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Abstract
Background: Autosomal recessive ataxias represent a group of clinically overlapping disorders. These include ataxia
with oculomotor apraxia type1 (AOA1), ataxia with oculomotor apraxia type 2 (AOA2) and ataxia-telangiectasia-like
disease (ATLD). Patients are mainly characterized by cerebellar ataxia and oculomotor apraxia. Although these
forms are not quite distinctive phenotypically, different genes have been linked to these disorders. Mutations in the
APTX gene were reported in AOA1 patients, mutations in SETX gene were reported in patients with AOA2 and
mutations in MRE11 were identified in ATLD patients. In the present study we describe in detail the clinical features
and results of genetic analysis of 9 patients from 4 Saudi families with ataxia and oculomotor apraxia.
Methods: This study was conducted in the period between 2005-2010 to clinically and molecularly characterize
patients with AOA phenotype. Comprehensive sequencing of all coding exons of previously reported genes related
to this disorder (APTX, SETX and MRE11).
Results: A novel nonsense truncating mutation c.6859 C > T, R2287X in SETX gene was identified in patients from
one family with AOA2. The previously reported missense mutation W210C in MRE11 gene was identified in two
families with autosomal recessive ataxia and oculomotor apraxia.
Conclusion: Mutations in APTX , SETX and MRE11 are common in patients with autosomal recessive ataxia and
oculomotor apraxia. The results of the comprehensive screening of these genes in 4 Saudi families identified
mutations in SETX and MRE11 genes but failed to identify mutations in APTX gene.
Background
Ataxia with Oculomotor Apraxia (AOA) is an autosomal
recessive cerebellar ataxia (ARCA) mainly characterized by
ataxia, oculomotor apraxia and choeroathetosis [1]. Two
clinically overlapping forms were characterized; AOA1
(MIM# 208920) and AOA2 (MIM# 606002). Patients with
AOA1 present with cerebellar ataxia and oculomotor
apraxia between ages 2 and 18 years old [2] accompanied
later in life by limb dysmetria and sensory-motor neuropa-
thy which may be associated with dystonia or mental
retardation, hypoalbuminemia, hypercholesterolemia and
normal immunoglobulins and alpha-fetoprotein levels.
There is no evidence of chromosomal instability and no
reported tumor predisposition in these patients [3].
Patients with AOA2 present with gait ataxia, cerebellar
atrophy, sensory-motor neuropathy, ocular-motor apraxia
and elevated immunoglobulins and alpha-fetoprotein
levels with an age of onset (10-22years)[4]. In addition
patients with Ataxia-Telangiectasia-Like Disorder (ATLD
also known as MRE11 ataxia MIM# 604391) present with
early onset ataxia and oculomotor apraxia [5]
Although these forms may not be quite distinctive
phenotypically, they are genetically heterogeneous.
Mutations in the APTX gene located on chromosome
9p13.3 were identified in patients with AOA1. These
include; missense, nonsense, splice mutations, single
base insertions and deletions [2,6-9]. A deletion of the
whole APTX ORF was reported in one family with
AOA1 phenotype [6]. Most mutations were clustered
between codons 198-280. Moreover; recurrent muta-
tions were reported in some populations; (689insT,
P206L) in Japanese patients and (W279X) in Portuguese
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families [6]. The APTX gene encodes a histidine-triad
(HIT) protein known as aprataxin [8].
Aprataxin is a nuclear protein of three domains; a fork-
head-associated (FHA) domain that mediates protein-
protein interaction with molecules that respond to DNA
damage such as binding to DNA single strand break
repair scaffold protein (XRCC1) and binding to DNA
double strand break repair scaffold protein (XRCC4).
Aprataxin also contains a histidine triad (HIT) domain
and a COOH terminal zinc finger domain [7,8,10,11], the
HIT domain is similar to Hint, a universal conserved
AMP-lysine hydrolase, studies showed that Aprataxin has
an active site dependent AMP lysine and GMP lysine
hydrolase activity that also depends on the zinc finger for
protein stability and on the FHA domain for enzyme
activity [11].
A number of missense, nonsense and frameshift muta-
tions in the SETX gene located in 9q34 were identified in
patients with AOA2 and a duplication covering exons 7-
10 was also identified in a patient with AOA2 [12,13].
SETX gene is also mutated in the autosomal dominant
form of juvenile amyotrophic lateral sclerosis (ALS4) and
tremor/ataxia syndrome [14,15]. Most reported muta-
tions in AOA2 patients were clustered in exons 6 and 8
and a common hot spot mutation at codon 1363 result-
ing in a change from amino acid arginine to a truncating
codon was recurrent in families from Portugal, Cabe
Verde and Spain [12]. Senataxin, the product of SETX is
a 2677 amino acid protein which harbors a C-terminus
7-motif domain (DNA/RNA helicase domain) found in
helicases superfamily1, suggesting that senataxin my play
a role in DNA repair [12,16]. Mutations in one of the
MRN complex genes; MRE11 located in 11q21 were
reported in patients with ATLD [5,17,18]. In the current
study we describe the clinical phenotypes and molecular
characterization of 9 patients with autosomal recessive
ataxia and oculomotor apraxia from 4 unrelated consan-
guineous families. We identified a novel truncating muta-
tion R2287X in SETX in one family in addition to the
previously reported mutation W210C in MRE11 gene in
two families. These findings emphasize on the role of
these genes in such disorders.
Methods
Families and samples
This study was ethically approved (RAC#2050036) and
conducted in the period between 2005-2010 at King
Faisal Special hospital and Research Center (KFSHRC)
which is a major tertiary care hospital in Saudi Arabia.
The medical records databases were requested to pro-
vide us with all patients diagnosed with ataxia and/or
oculomotor apraxia. We were able to identify and enroll
four families (9 affected individuals) from the central
and western regions of Saudi Arabia presented with
clinical features that falls within Ataxia Oculomotor
Apraxia spectrum. Consanguinity is a major feature in
all these families. Clinical details of patients are sum-
marized in Table 1 and pedigrees are presented in
Figure 1. Further details on these families are described
below:
Family A: two sisters aged 27 (IV:1) and 23 (IV:3)
were examined, age of onset 14 and 20 years respec-
tively; parents were related, the other three siblings were
normal. Only the elder sister had clear oculomotor
apraxia, very slow horizontal saccadic ocular movement,
vertical saccads were minimally affected, smooth pursuit
ocular movement were poor in all directions. Frequent
head thrusts were noted, tendon reflexes were absent
and sensor nerve action potentials were reduced while
alphaphetoprotein was elevated.
Family B: Parents were first cousins. One male aged 33
(II:2)and one female aged 31 (II:3)were examined the
remaining four siblings were normal. Progressive ataxia
started at ages15 and 17 years and patients were still
ambulatory with difficulty at the stated age. Vertical
more than horizontal oculomotor apraxia was noted with
absent voluntary vertical eye movement and intact oculo-
cephalic reflex. In addition both patients had cognitive
and behavioral problem with forgetfulness, lack of atten-
tion, word finding difficulty, emotional liability, impulsiv-
ity and disinhibition with fragmented and reversed sleep
patterns. Tendon reflexes and normal nerve conduction
studies were normal. EEG was diffusely dysarythmic.
Brain MRI showed no cerebellar atrophy.
Family C: Parents were second-degree cousins, 25 years
old sister (II:1) and 23 years old brother (II:2) were exam-
ined, and one niece was similarly affected (not examined).
Gait and limb ataxia were noted around 2-3 years of age,
ocular apraxia started around age of 10 years, smooth
pursuit ocular movement was absent in all directions and
saccadic eye movement was also defective. Small saccads
were substituting for the large one and required head
thrusts. Brain MRI showed severe cerebellar atrophy and
Brain FDG-PET showed cerebellar hypometabolism.
Decreased vibration sense was noted distally, and axonal
mainly sensory polyneuropathy was observed with nerve
conduction study.
Family D: Parents were first cousins. Three affected
individuals, 30 (V:1), 27 (V:2) and 16 (V:7) years old
were examined. Five other nephews and nieces were his-
torically affected but not studied. Ataxia was noted at
age two years and oculomotor apraxia was variable
among the affected individuals with very slow saccadic
eye movement and impaired horizontal more than verti-
cal pursuit eye movement with head thrusts. Vibration
senses were decreased distally and tendon reflexes
were absent. There was no cognitive impairment. Dys-
tonic and choreatic movement were frequently noted.
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Table 1 Clinical and biochemical characteristics of AOA patients participated in the study
Family A Family B Family C Family D
Patient IV.1 IV3 II.2 II.3 II.1 II.2 V.1 V.2 V.7
Sex F F M F F M M F F
Age 27 23 33 31 25 23 30 27 16
Age of onset 14 20 15 17 3 2 2 3 2
Ataxia +++ ++ ++ +++ ++ + ++ +++ +++
Ocular Apraxia ++ NP + + ++ +++ ++ + +
Dysarthria + NP + + ++ + + + NP
Mental subnormality NP NP ++ ++ + + NP NP NP
Cerebellar atrophy ++ ++ NP NP ++ ++ ++ ++ ++
Tendon reflexes Absent Absent Normal Normal Absent Absent Absent Absent Absent









AFP (n 0-15) 24.4 51.0 2.0 1.8 3.5 2.5 4.3 4.2 4.1
Gene/Mutation SETX/R2287X MRE11/W210C No mutations in
APTX, SETX, MRE11
MRE11/W210C
M male, F female, NP Not present, + mild, ++ moderate, +++ severe.
Figure 1 Pedigrees of AOA1 and AOA2 families. Each family has at least two affected individuals and autosmal recessive mode of
inheritance.
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The disease was relentlessly progressive and patients
became wheelchair-bound around age of 18 years. Intra-
familial variability was noticeable with the middle
patient more severely affected.
Samples
Blood samples were obtained with informed consent
from family members in adherence with institutional
and international guidelines (RAC#2050036). DNA was
extracted from 3 ml of whole blood using Gnetra sys-
tems according to manufacturer conditions. DNA con-
centrations were determined.
Amplification and sequence of APTX, SETX and MRE11
genes
The coding exons and flanking intronic sequences of
APTX, SETX and MRE11 genes were amplified (primers
are available upon request). PCRs were performed in a
25 μl reaction volume containing 2.5 μl of 10× reaction
buffer (15 mM MgCl2,), 0.2 mM dNTPs, 10 μM of
ARMS primers, 5 μM of IC primers, 1 U of HotStarTaq
polymerase (QIAgen), and 10 ng genomic DNA. Cycling
parameters were 94°C for 10 min, 30-35 cycles of 94°C
for 45 sec, 52-59°C for 45 sec and 72°C for 45 sec fol-
lowed by a final elongation step at 72°C for 10 min. Pro-
ducts were visualized on ethidium bromide stained
agarose gels.
PCR products were sequenced using ABI Prism Big
Dye™Terminator ready reaction cycle sequencing kit
(Applied Biosystems). Products were electrophoresed
using automated ABI DNA sequencer. Sequencing
results were exported in one of several formats for
visualization and analysis of sequence using Lasergene 6
software package.
Microsatellite Analysis
Microsatellite markers flanking APTX (D9S83, D9S1788,
D9253) and SETX (D9S1861, D9S179, D9S1847,
D9S2127) were used for further genotype analysis. PCR
was performed using 0.24 uM primers (forward primer
FAM labeled), 2.5 mM dNTP, 10× buffer and 1 Unit of
Taq polymerase and 10 ng of DNA in a 10 ul reaction.
Products were run on a MegaBace 1000 capillary
sequencer. Results were analyzed using MegaBase
Genetic profiler V.2 (Amersham Biosciences).
Linkage analysis
10K SNP genotyping was performed as detailed by Affy-
metrix on the GeneChip® Human Mapping 10K Array
Xba 142 2.0. In summary, 50ng of genomic DNA was
digested with 10 units of XbaI (New England Biolabs,
MA) for 2 hours at 37°C. T4 DNA Ligase was used to
ligate the Xba Adaptor (Affymetrix, CA) to the digested
ends. The ligated samples were diluted with water and
were used as PCR templates for primers specific to the
adaptor sequence with the following cycling parameters:
95°C for 3 minutes initial denaturation, 95°C 20 seconds,
62.5°C 15 seconds, 72°C 15 seconds for a total of 35
cycles, followed by 72°C for 7 minutes final extension.
PCR products were then purified with salt precipitation
and fragmented at 37°C for 45 minutes. The fragmented
DNA was then end-labeled with biotin using 1.5 units of
terminal deoxynucleotide transferase (TD) the reaction
was incubated at 37°C for 2 hours. Labeled DNA was
then hybridized onto the 10K Mapping Array DNA Chip
at 48°C. The hybridized array was washed, stained, and
scanned according to the manufacturer’s instructions.
SNP genotypes were generated using affymetrix GCOS
1.4 software. Multipoint LOD score was performed with
easy linkage software package.
Results
Mutations in SETX gene
A novel truncating mutation (c.6859 C > T, R2287X) in
exon 20 of the SETX gene was identified as the disease
causing mutation in family A. All affected individuals
were homozygous for this mutation while other family
members were heterozygous carrying both wild-type
and mutant allele (Figure 2).
Variants Identified in SETX and APTX genes
A total of 11 missense, silent and intronic variants were
identified in both genes. These include APTX c836+91t
> c. SETX c846+20a > g, 846+30t > c, T1855A, D1937,
T2587V and the previously reported variants in SETX
Figure 2 Ssequence chromatogram showing the region of
exon 20 of SETX gene where the R2287X (c.6859 C > T) is
located. (A) A normal control sequence trace homozygous for the
normal allele (harbouring a “C” at position 6859). (B) The patient is
homozygous for the mutant allele (harbouring a “T” at position
6859). Arrow points to the base substitution.
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gene Y359, H1049, D1192E, G1252R and I1385V[12].
None of these variants segregated with the disease in
families B and C.
Haplotype analysis in Family D
Haplotype results using both microsatellite and intra-
genic markers excluded both APTX and SETX genes as
the underlying genetic cause in this family.
Linkage analysis
linkage analysis on family D revealed a disease locus in
4 Mb regions on the long arm of chromosome 11 with
a maximum multipoint logarithm of odds (LOD) score
of 3.2 harboring MRE11 gene.
Mutations in MRE11 gene
Sequencing analysis identified a previously reported mis-
sense mutation in exon 7 of MRE11 gene (c.630 G > C,
W210C) in family D. This mutation was also identified
in affected individuals from family B (Figure 3).
Discussion
Inherited diseases of the nervous system are medically
and genetically heterogeneous group of abnormalities.
Mutations in LMNA, GAN1, KCC3, TDP1, APTX, SETX
and MRE11 were found to be the causes of autosomal
recessive axonal neuropathies [19-21]. Ataxia with Ocu-
lomotor Apraxia type1 (AOA1), Ataxia with Oculomotor
Apraxia type2 (AOA2), Ataxia with Oculomotor Apraxia
type3 (AOA3), Ataxia Talengestasia (AT) and Ataxia
Talengestasia Like (ATLD) represent a group of overlap-
ping recessively inherited ataxias[22]. APTX and SETX
gene mutations were identified in patients with AOA1
and AOA2 from different populations, indicating that
these genes represent the common underlying genetic
cause for AOA in these patients. In this study, a novel
homozygous truncating mutation R2287X in SETX gene
was identified in the 3 affected individuals in Family A.
The SETX gene codes for senataxin, a protein that con-
tains a DNA/RNA helicase and is involved in DNA
repair.
Most reported mutations in SETX were present in
exon 8 resulting in loss of the C- terminus motifs but
this mutation is localized in exon 20 of the gene result-
ing in a protein that retains the C terminus helicase
domain, thereby indicating the importance of other
domains.
Such domains could possibly be involved in the inter-
action with other proteins involved in transcription and
RNA processing including RNA polymeraseII, suggestive
of an additional role for senataxin in the coordination of
different transcription events[23].
Three Saudi families from consanguineous marriages
with ataxia and oculomotor apraxia were enrolled in this
study (Table 1). Although AOA1 affected individuals
with mutations in APTX have been identified world wide;
13 individuals from 3 unrelated Tunisian family [6],
2 unrelated individuals from Germany [24], 3 unrelated
Italian individuals [25], 2 American children [26] and 4
Caucasians with ataxia and CoQ10 deficiency [27], yet
comprehensive screening by direct sequencing of the
APTX gene did not identify any mutations in these 3
Saudi families. Microsatellite analysis further excluded
this gene as disease causing in these families. However,
linkage analysis on family D with 3 affected individuals
identified a locus harboring MRE11 gene which is
mutated in ATLD where there is progressive cellular
degeneration, ocular apraxia and absence of ocular telan-
giectasia [17,18,28]. Sequencing of MRE11 in family D
members identified the previously reported W210C mis-
sense mutations in all affected individuals from both
families B and D. W210C missense mutation was identi-
fied in 10 Saudi patients with ATLD [5]. Some studies
suggested that the signaling related function of the
MreII/Rad50/Nbs1 (MRN) complex is related to the
ATM function in mammalian cells, as certain compo-
nents of the MRN complex act substrates for ATM
which is in turn important for S phase checkpoint activa-
tion and cell survival following double-strand breaks [29].
Screening all these genes in affected individuals of family
C failed to detect any pathogenic segregating mutation,
however, we didn’t check for regulatory mutations or
large deletions. Moreover, the two affected siblings in
this family had ataxia and oculomotor apraxia with
no cerebellar atrophy and normal tendon reflexes and
they may belong to a similar overlapping form of ataxia.
None of our patients has features suggestive of ataxia
Figure 3 Exon 7 of MRE11 gene sequence showing the location
of W210C (c.630 G > C) mutation. (A) Wild type sequence. (B)
Heterozygous (C) Homozygous for the mutant allele. Arrow points
to the base substitution.
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telangiectasia. Particularly there was no repeated infec-
tion, tumor appearance or changes in immunoglobulins
in these families.
We screened nine affected individuals from 4 families
with ataxia and oculomotor apraxia for mutations in the
reported genes APTX, SETX and MRE11 and identified
a novel truncating mutation in SETX gene in one family
and a previously reported missense mutation in MRE11
gene in two families.
Conclusion
Identification of a novel truncating mutation in SETX
gene in a Saudi family with AOA2 and the common
reported mutation W210C in MRE11 in two families
with ataxia and oculomotor apraxia supports the invol-
vement of these genes in the disease progression. Lack
of mutations in APTX, SETX and MRE11 genes in the
third family diagnosed with ataxia and oculomotor
apraxia and no cerebellar atrophy suggests the involve-
ment of another mechanism for the development of this
disorder.
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